Brazil approves Knight Therapeutics' TAVALISSE for chronic immune thrombocytopenia treatment

Knight Therapeutics' Brazilian affiliate received regulatory approval for TAVALISSE (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) who did not respond to previous treatments. This approval addresses a significant unmet medical need in Brazil, offering a new treatment option with a different mechanism of action. The drug's launch is expected in the second half of 2026, following successful clinical trials demonstrating its efficacy and manageable side effects. Knight has also pursued regulatory approvals for TAVALISSE in other Latin American countries, expanding its market presence.